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Introduction: Ischemic stroke remains one of the most debilitating diseases and is the
fifth leading cause of death in the US. The ability to predict stroke outcomes within
the acute period of stroke would be essential for care planning and rehabilitation. The
Blood and Clot Thrombectomy Registry and Collaboration (BACTRAC; clinicaltrials.gov
NCT03153683) study collects arterial blood immediately distal and proximal to the
intracranial thrombus at the time of mechanical thrombectomy. These blood samples
are an innovative resource in evaluating acute gene expression changes at the time
of ischemic stroke. The purpose of this study was to identify inflammatory genes and
important immune factors during mechanical thrombectomy for emergent large vessel
occlusion (ELVO) and which patient demographics were predictors for stroke outcomes
(infarct and/or edema volume) in acute ischemic stroke patients.
Methods: The BACTRAC study is a non-probability sampling of male and female
subjects (≥18 year old) treated with mechanical thrombectomy for ELVO. We evaluated
28 subjects (66± 15.48 years) relative concentrations of mRNA for gene expression in 84
inflammatory molecules in arterial blood distal and proximal to the intracranial thrombus
who underwent thrombectomy. We used the machine learning method, Random Forest
to predict which inflammatory genes and patient demographics were important features
for infarct and edema volumes. To validate the overlapping genes with outcomes, we
perform ordinary least squares regression analysis.
Results: Machine learning analyses demonstrated that the genes and subject factors
CCR4, IFNA2, IL-9, CXCL3, Age, T2DM, IL-7, CCL4, BMI, IL-5, CCR3, TNFα, and
IL-27 predicted infarct volume. The genes and subject factor IFNA2, IL-5, CCL11,
IL-17C, CCR4, IL-9, IL-7, CCR3, IL-27, T2DM, and CSF2 predicted edema volume.
The overlap of genes CCR4, IFNA2, IL-9, IL-7, IL-5, CCR3, and IL-27 with T2DM
predicted both infarct and edema volumes. These genes relate to a microenvironment
for chemoattraction and proliferation of autoimmune cells, particularly Th2 cells
and neutrophils.
Martha et al. Cytokines and Chemokines as Predictors of Stroke
Conclusions: Machine learning algorithms can be employed to develop prognostic
predictive biomarkers for stroke outcomes in ischemic stroke patients, particularly in
regard to identifying acute gene expression changes that occur during stroke.
Keywords: ischemic stroke, machine learning, gene expression, cytokines, chemokines
INTRODUCTION
Ischemic stroke is the fifth cause of death in the United States,
accounting for 87% of all strokes (1). Approximately 800,000
individuals are affected per year and ischemic stroke is the
primary cause of severe long-term disability (1). When a major
cerebral artery is blocked by a thrombus, the occlusion causes
deprivation of oxygen, glucose, and other essential nutrients
to the brain which results in necrotic cerebral tissue (2).
Current treatments focused on recanalization of the occluded
cerebral artery for emergent large vessel occlusions (ELVO) via
intravenous administration of tissue plasminogen activator (tPA)
and/or endovascular mechanical thrombectomy (3–5). Stroke
patients must be given tPA within a narrow window of 4.5 h,
while mechanical thrombectomy has an extended window of
intervention up to 24 h post-stroke (6–8). However, ischemic
stroke patients must meet particular imaging or time criteria
to receive either or both treatments, and many patients are out
of the “window of opportunity,” and receive only supportive
medical care (9).
With early reperfusion to the cerebral artery, at risk
tissue in the penumbra may be salvaged (10, 11). Even if
blood flow is restored, neurons in the penumbra face major
challenges to their survival, such as acidosis, ion pump failure,
excitotoxicity, inflammatory response, and the breakdown the
blood brain barrier (BBB) (12–14). Inflammation following
an acute ischemic stroke is multifaceted, and is part of the
normal pathological processes involved in the post-ischemic
brain. Within the first few hours, there is a rapid activation
of resident microglia that start to release proinflammatory
mediators from the ischemic endothelium and brain parenchyma
[including interleukin-(IL)1β, IL-6, IL-12, IL-23, and tumor
necrosis factor-α (TNF-α)] (15–17). Furthermore, there is an
activation of peripheral immune cells including neutrophils and
T-cells that can cross the damaged BBB and accumulate at
the injury site in the microvascular environment. In this acute
phase of ischemic stroke more extensive damage occurs with the
associated increased intracranial pressure leading to malignant
cerebral edema, neuronal death, hemorrhagic transformation,
and mortality (18–21).
Mechanical thrombectomy has greatly improved the ability
to restore blood flow and improve patient outcomes, even
when used in selected patients up to 24 h post-stroke onset
(5, 22). The process of thrombectomy permits us to extract blood
directly in the vicinity of the infarct from a stroke patient to
provide the first glimpse into cellular/molecular events occurring
during an ischemic stroke. Through the standard thrombectomy
process, we can isolate distal blood within the artery immediately
downstream from the clot, peripheral blood that is proximal
to the clot (systemic arterial blood in the cervical carotid
artery), and the thrombus itself upon removal from the human
subject (23).
Understanding of molecular and cellular changes
intraluminally in ischemic stroke may provide develop deeper
insights into the inflammatory pathways involved, and could lead
to the identification of prognostic biomarkers in stroke patients.
This information could potentially provide benchmarks to study
responses to treatment and aid in development of new therapies.
The purpose of this study was to identify inflammatory genes
and important immune mediators at the time of mechanical
thrombectomy and which patient demographics were predictors
for stroke outcomes (infarct and/or edema volume) in acute
ischemic stroke patients.
METHODS
Study Design
This study was developed from the Blood and Clot
Thrombectomy Registry and Collaboration (BACTRAC)
protocol: a prospectively enrolling tissue bank for emergent
large vessel occlusion (ELVO) (clinicaltrials.gov NCT03153683)
(23). The BACTRAC study is a non-probability sampling of
subjects over 18 years old, conducted at a large academic
comprehensive stroke center in central Kentucky, and
who were treated with mechanical thrombectomy for
ELVO ischemic stroke. While the BACTRAC tissue bank
is continuously enrolling, data for this study was collected
from subjects enrolled May 2017 through January 2019.
The Institutional Review Board approved this study, and
informed consent was obtained from all subjects or legally
authorized representatives.
Sample Population
Subjects (≥18 years old) were eligible for inclusion if they
were hospitalized with a diagnosis for an ischemic stroke
and underwent thrombectomy procedure for ELVO. Subjects
were candidates for inclusion if they met criteria: informed
consent was signed and dated by subject or legally authorized
representative within 24 h post-thrombectomy, confirmation of
acute ischemic stroke based on clinical and radiographic imaging
(CT and/or MRI), intra-arterial thrombectomy as determined
by neurointerventional radiology (NIR) physician, an acute
thromboembolus within an intracranial artery and underwent
endovascular thrombectomy procedure. Subjects were excluded
if baseline urine pregnancy test was positive and/or breastfeeding
and/or concurrently participated in treatment studies.
Data Collection
A medical record review was conducted to collect
admission clinical and demographic variables. These
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variables included age, sex, ethnicity, height, weight,
body mass index (BMI), comorbidities, smoking status,
National Institutes of Health Stroke Scale (NIHSS),
baseline computerized tomography (CT) and/or magnetic
resonance imaging (MRI) scan to verify large vessel occlusion
stroke/thrombectomy eligibility and CTA collateral score,
and time of last known normal (LKN) symptom (prior to
ischemic stroke).
Tissue removal and tissue banking protocols were previously
published in detail (23). In brief, this was a collaborative effort
among the NeuroInterventional Radiology (NIR) service line
and our Center for Advanced Translational Stroke Science.
At the beginning of the mechanical thrombectomy procedure,
during initial access through the clot to the distal intracranial
vessels, the NIR physician backbleeds the microcatheter to
determine if they are distal to the distal end of the thrombus.
Through this, 1ml of whole arterial blood from themicrocatheter
(0.021 inch inner lumen diameter) was collected. Simultaneously,
the collection of 7ml of whole arterial peripheral blood was
collected from the cervical parent artery (internal carotid
artery or vertebral artery) during backbleeding while initially
suction for thrombectomy. The distal (intracranial) and proximal
(peripheral) blood samples were handed off to the on-call
research associates who immediately processed the specimens in
the wet laboratory adjacent to the angiography suite.
An additional medical chart review was conducted to
gather post-thrombectomy endpoint variables: last known
normal (LKN) symptom to thrombectomy completion time
(infarct time), thrombolysis in cerebral infarction (TICI)
scores, and NIHSS at discharge. A blinded neuroradiologist
evaluated post-thrombectomy computed tomography (CT)
imaging and/or magnetic resonance imaging (MRI) for
infarct and edema volumes, and hemorrhagic grade. Clinical
and demographic variables, along with post-thrombectomy
endpoints were deidentified and maintained in our institution’s
REDCap software.
RNA Extraction and Amplification
The extraction of total RNA from the cellular pellet/buffy
coat was collected from the stored distal and proximal arterial
blood samples using the Nucleospin Blood Kit (Macherey-Nagel,
Düren, Germany), per manufacturer protocol. Nanodrop Lite
Spectrophotometer (Thermo-Fisher Scientific; Waltham, MA)
estimated the quantity of total RNA based on the A260/A280
ratio. To validate total RNA, RNA integrity numbers (RIN)
values were obtained from the hospital’s Genomics Core facility.
The assessment and analysis of RNA integrity was evaluated
with Eukaryote Total RNA Nano assay on the Agilent 2100
Bioanalyzer (Agilent Technologies, Santa Clara, CA) and with
associated Agilent 2100 Bioanalyzer expert software. The mean
RIN values (±SD) for distal and proximal arterial blood samples
were 8.89 ± 0.41 (range from 8.30 to 9.60) and 6.98 ± 0.29
(range from 6.60 to 7.50), respectfully. The RIN values indicate
moderate to high quality RNA with minimal degradation (24).
RT2 First Strand Kit (Qiagen) was used to synthesize cDNA
which were analyzed for gene expression using Qiagen RT²
Profiler PCRArray Human Inflammatory Cytokines & Receptors
for 84 genes associated with inflammation and evaluated with
StepOnePlus Real-Time PCR System interfaced with StepOne
software (Applied Biosystems, Foster City, CA). Each gene
array plate had five housekeeping genes (ACTB, B2M, GAPDH,
HPRT1, and RPLP0) to normalize the gene expression data by
using 11CT method. The distal blood data for each gene was
compared to proximal blood data for each subject. Proximal
blood samples were used as an internal control for each patient,
since there is not a true control. Since the cervical segments have
circulating blood, we believe these are equivalent to arterial blood
taken from peripheral arterial location.
Data Analysis
Descriptive and frequency statistics were obtained and used
to characterize male and female ischemic stroke subjects.
Comparisons were made for subject demographics and baseline
characteristics using SPSS, version 26 software (IBM, Armonk,
NY). Statistical significance (p-value of 0.05) for group
differences were assessed by independent t-tests for continuous
variables and Chi-square or Fisher exact tests of associations
based on categorical (ordinal and binary) variables. The gene
expression mean fold change values were assessed with Scikit-
learn Python package (v0.21.2) for machine learning analysis
(25). Statesmodels Python package (v0.10.1) was used for
ordinary least squares (OLS) regression analysis (26).
Machine Learning
For machine learning analysis, the demographics data used
included variables: sex, age, race/ethnicity, BMI, comorbidities
(hypertension, type 2 diabetes, hyperlipidemia, previous stroke,
and atrial fibrillation), and two stroke outcomes (infarct and
edema volumes). The gene expression dataset included 84
inflammatory genes. Any variables in the two stroke outcome
datasets were dropped if the proportion of missing values were
more than 40%. After pre-processing 89 variables were in the
final dataset.
Predicting Infarct Volume
Predictive analysis was performed by using the infarct volume
as the response variable, and all gene expression variables as
predictors. The analysis was adjusted by using demographic
variables as covariates. Regression was used to perform the
predictive analysis task. Since there was a relatively small sample
size with a mild number of predictors (i.e., 28 subjects with 89
predictors), a widely used machine learning method, Random
Forest (RF) (27, 28) was employed to complete the analysis. This
method was used because of the reliable performance on small
sample datasets with mixed categorical and continuous variables.
RF is an ensemble of decision trees, where each internal node
represents a condition, or test, on a single predictor, aiming to
split the dataset into two so that each had a similar response
values. RF provides versatile, accurate, and stable predictions
for supervised machine learning tasks such as regression as well
as measuring the relative importance of each predictor. The
importance score of a predictor is calculated by how much the
variance is reduced or information gain is increased across all
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nodes that were used. The importance scores were scaled so the
sum equals one.
Hyper-parameters of RF were selected in a coarse-to-fine
approach using k-fold cross-validation (CV), which partitions
the training dataset into k parts evenly, then rotationally uses
k-1 parts to train the machine learning model and tests the
model with the remaining one part. The parameters were first
selected using the 5-fold CV, then tuned the parameters around
the selected value using the 10-fold CV. Predicting performance
of RF was optimized in mean squared error (MSE), which is
minimized for the optimal model.
With the selected hyper-parameters, the importance of
features using RF were ranked. Ranking may be affected by
randomness of RF due to the correlations between some features.
Therefore, we programed RF 100 times and collected the mean
values of the feature importance. The number of possible orders
of the features is combinatorically large, this approach can
effectively reduce but cannot fully eliminate the effect of the
correlation between features.
Predicting Edema Volume
Similar to the prediction of infarct volumes, this was a regression
task by using edema volumes as a response variable and the
remaining gene variables as predictors. The analysis was adjusted
using the demographic variables as covariates as done for the
analysis of infarct volumes. Using similar preprocessing and cross
validation with RF, the negative MSE was used as a score and
maximized for optimal RF model. The relative importance of the
predictors were also obtained for this task.
Stroke Outcomes of Infarct and Edema
Volumes
Noncontrast head CT and CTA of the head and neck were
obtained upon presentation to the emergency department during
initial assessment for acute ischemic stroke. Siemens SOMATOM
Definition Edge and SOMATOM Force CT scanners were used
for all CT studies. CTA collateral scores were determined
using maximum intensity projection images from CTA of the
head with a scoring system described in previous work by
Souza et al. (29). MRI and CT of the head without contrast
were obtained following thrombectomy. MRI was performed
using Siemens MAGNETOM Aera and MAGNETOM Skyra
machines at magnetic field strength of 1.5 and 3.0 Tesla,
respectively. Hemorrhage grade, infarct volume, and edema
volume were determined on post-thrombectomy MRI of the
head or CT of the head if MRI was unavailable. Hemorrhage
grade was determined using a grading scale described by
Hacke et al. (30). Infarct volumes and edema volumes were
calculated using post-thrombectomy MRI, or using CT if MRI
was unavailable. Imaging included the entire brain on both
MRI and CT examinations, and all images/slices were visually
assessed for infarction or edema. When MRI was available,
diffusion weighted images (DWI) were used to calculate infarct
volumes, and T2 FLAIR images were used to calculate edema
volumes. The areas of abnormal signal (restricted diffusion
on DWI or hyperintense signal on T2 FLAIR) were manually
segmented and analyzed to determine volume using ITK-SNAP
software (www.itksnap.org) (31). When MRI was unavailable,
CT of the head was used to calculate both infarct and edema
volume. As infarct and edema were indistinguishable on CT,
the same value was used for both after manually segmenting
the area of abnormal hypoattenuation using ITK-SNAP. All
imaging assessment, including hemorrhage grade, CTA collateral
score, infarct volume, and edema volume was performed by an
experienced neuroradiologist in a blinded fashion.
RESULTS
Sample Characteristics
Twenty-eight subjects underwent mechanical thrombectomy
during the study period. The mean age of our subjects were 66
± 15.48 years, primarily female (61%), and the majority were
Caucasian (86%).Table 1 presents baseline subject characteristics
and comparisons based on sex. Similarities were exhibited
between the subjects for BMI, comorbidities (hypertension, atrial
fibrillation, type 2 diabetes, hyperlipidemia, previous stroke,
chronic obstructive pulmonary disease, and coronary artery
disease), smoking status, stroke location, hemorrhagic grade,
CTA collateral scores, infarct and edema volumes. The NIHSS
on average went from admission score of 17 ± 6.56 to discharge
score of 11± 9.54 post-thrombectomy. More males (81.8%) than
females (41.2%) exhibited full perfusion to the occluded artery
post-thrombectomy with a TICI score of 3 (p= 0.034). The mean
infarct time (LKN to thrombectomy completion time) for males
was∼7 h vs. almost 10 h for females (p= 0.093).
Prediction of Infarct Volume With Machine
Learning
For predicting infarct volume, the covariates including all 84
genes and the 10 demographic variables are all ranked in
importance scores. For the ranked top k, k= 1–84, covariates we
perform 5-fold CVs to find the optimal RF model and obtain the
corresponding optimal performance, which is scored in negative
MSE. The importance values of the top 10 covariates, 10 for
predictive analysis of infarct volume are given in Table 2. They
are in descending order as follows: CCR4, IFNA2, IL-9, CXCL3,
age, type 2 diabetes (T2DM), IL-7, CCL4, BMI, IL-5, CCR3,
TNFα, and IL-27.
Prediction of Edema Volume With Machine
Learning
For predictive analysis of edema volume, in a similar way to
the predictive analysis of infarct volume, we obtain the optimal
performance for the top k covariates, k = 1–84. The importance
values of the top 10 most important covariates are shown in
Table 3. They are in descending order as follows: IFNA2, IL-
5, CCL11, IL-17C, CCR4, IL-9, IL-7, CCR3, IL-27, T2DM,
and CSF2.
When using infarct and edema volumes as outcome variables,
we observed selected gene subsets for these two predictive
analysis have a significant overlap. The intersection of the top
10 genes from the two stroke outcomes are seven genes with
T2DM, these include CCR4, IFNA2, IL-9, IL-7, IL-5, CCR3, and
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TABLE 1 | Baseline demographics and characteristics for ischemic stroke
subjects.
Males
(n = 11)
Females
(n = 17)
p-value
Age (years) 68 ± 17.07 64 ± 14.77 0.606
Ethnicity
African-American 2 (18.2) 0 (0.0) 0.072
Caucasian 9 (81.8) 15 (88.2) 0.650
Unknown 0 (0.0) 2 (11.8) 0.254
BMI
Under/normal weight 4 (36.4) 9 (52.9) 0.409
Overweight 6 (54.5) 6 (35.3) 0.333
Obese 0 (0.0) 0 (0.0) –
Morbidly obese 1 (9.1) 2 (11.8) 0.831
Comorbidities
Hypertension 4 (36.4) 11 (64.7) 0.346
Atrial fibrillation 3 (27.3) 5 (29.4) 0.907
Diabetes 1 (9.1) 6 (35.3) 0.127
Hyperlipidemia 3 (27.3) 2 (11.8) 0.313
Previous stroke 2 (18.2) 3 (17.6) 0.973
COPD 1 (9.1) 3 (17.6) 0.545
CAD 3 (27.3) 1 (5.9) 0.123
Smoking status
Never 5 (45.5) 11 (64.7) 0.333
Currently 4 (36.4) 4 (23.5) 0.481
Previously (>6 months) 2 (18.2) 2 (11.8) 0.650
NIHSS on admission 17 ± 8.04 16 ± 5.65 0.732
Minor stroke (1-4) 2 (18.2) 1 (5.9) 0.322
Moderate stroke (5-15) 3 (27.3) 6 (35.3) 0.671
Moderate/severe (16-20) 2 (18.2) 6 (35.3) 0.346
Severe stroke (≥21) 4 (36.4) 4 (23.5) 0.481
NIHSS at discharge 14 ± 14.21 9 ± 7.32 0.249
Minor stroke (1-4) 4 (36.4) 6 (35.3) 0.808
Moderate stroke (5-15) 4 (36.4) 7 (41.2) 0.818
Moderate/severe (16-20) 1 (9.1) 2 (11.8) 0.838
Severe stroke (≥21) 2 (18.2) 1 (5.9) 0.322
TICI score
2A ≤ 50% Perfusion 0 (0.0) 1 (5.9) 0.432
2B ≥ 50% Perfusion 2 (18.2) 9 (52.9) 0.070
3 = Full perfusion 9 (81.8) 7 (41.2) 0.034
LKN to thrombectomy
completion time
(minutes)
416 ± 231.88 582 ± 249.06 0.093
Stroke location
Left MCA 4 (36.4) 8 (47.1) 0.576
Right MCA 6 (54.5) 8 (47.1) 0.699
Basilar 1 (9.1) 1 (5.9) 0.747
Infarct volume (cm3) 87.90 ± 104.58 48.33 ± 62.30 0.219
Edema volume (cm3) 98.60 ± 116.01 48.52 ± 61.23 0.147
Hemorrhagic grade
None
4 (36.4) 4 (23.5) 0.481
HI1 4 (36.4) 7 (41.2) 0.808
H12 1 (9.1) 6 (35.3) 0.127
PH1 1 (9.1) 0 (0.0) 0.220
PH2 1 (9.1) 0 (0.0) 0.220
(Continued)
TABLE 1 | Continued
Males
(n = 11)
Females
(n = 17)
p-value
CTA collateral score
0 3 (27.3) 2 (11.8) 0.650
1 5 (45.5) 11 (64.7) 0.333
2 3 (27.3) 4 (23.5) 0.748
Values are mean ± SD or (%). Comparisons were performed with independent t-tests,
Chi-square, or Fisher exact tests based on distribution of data.
TABLE 2 | Importance values of top 10 variables for predicting infarct volume.
CCR4 0.077
IFNA2 0.063
IL-9 0.053
CXCL3 0.045
Age 0.038
Type 2 diabetes 0.036
IL-7 0.034
CCL4 0.029
BMI 0.028
IL-5 0.027
CCR3 0.023
TNFα 0.022
IL-27 0.021
TABLE 3 | Importance values of top 10 variables for predicting edema volume.
IFNA2 0.074
IL-5 0.070
CCL11 0.057
IL-17C 0.045
CCR4 0.045
IL9 0.044
IL-7 0.036
CCR3 0.035
IL-27 0.033
Type 2 diabetes 0.032
CSF2 0.025
IL-27. This overlapping subset of genes were regarded as themost
important associations at the time of mechanical thrombectomy.
Prediction of Stroke Outcomes With
Multiple Linear Regression
To validate this overlapping subset of genes, we perform ordinary
least squares (OLS) regression analysis with the top seven
covariates. The OLS results for predictors of infarct volume and
edema volume are shown in Tables 4, 5, respectively. To note,
the OLS was a statistical model that assumes a linear relationship
between the predictive outcome and the covariates. In contrast,
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TABLE 4 | OLS regression variables predicting infarct volume (n = 28).
Variable β P-value
CCR4 −0.733 0.740
IFNa2 −0.104 0.793
IL-9 12.146 0.017
Type 2 diabetes 69.942 0.026
IL-7 −5.277 0.217
IL-5 1.205 0.233
CCR3 −0.084 0.855
IL-27 −0.683 0.549
R2 = 0.654, adjusted R2 = 0.533, df = 8, F = 5.396, p = 0.001.
Durbin-Watson = 1.83.
TABLE 5 | OLS regression variables predicting edema volume (n = 28).
Variable β P-value
CCR4 −1.987 0.486
IFNa2 −0.099 0.848
IL-9 13.127 0.040
Type 2 Diabetes 57.469 0.140
IL-7 −8.326 0.134
IL-5 2.109 0.110
CCR3 0.083 0.889
IL-27 −0.729 0.693
R2 = 0.507, adjusted R2 = 0.334, df = 8, F = 2.938, p = 0.028.
Durbin-Watson = 1.69.
the machine learning model was capable of capturing potentially
highly non-linear relationship between the outcome and the
covariates (32, 33). Therefore, OLS may partially capture the
association between the outcomes and the covariates. IL-9 and
T2DM were predictors for infarct volume [F(8,27 = 5.396, p =
0.001). These predictors for infarct volume explained 53% of the
total variance in the model (Table 4). Similarly, we performed the
OLS analysis for predictors of edema volume. IL-9 was a predictor
for edema volume [F(8,27= 2.938, p= 0.028). IL-9 explains 33%
of the total variance found in the model (Table 5).
Gene Expression of Inflammatory Markers
and Ingenuity Pathways Analysis
Ten inflammatory genes (CCR4, IFNA2, IL-9, CXCL3, IL-
7, CCL4, IL-5, CCR3, TNFα, and IL-27) were recognized as
predictors for infarct volume had mean fold change ranging
from 2.56 to 35.06. While the inflammatory genes (IFNA2, IL-
5, CCL11, IL-17C, CCR4, IL-9, IL-7, CCR3, IL-27, and CSF2)
that were identified as predictors for edema volume had mean
fold change ranging from 3.98 to 42.61. The seven important
predictor genes (CCR4, IFNA2, IL-9, IL-7, IL-5, CCR3, and IL-
27) that overlapped both stroke outcomes had mean fold change
ranging from 3.98 to 35.06.
The mean fold changes for the 13 genes were analyzed
through the use of Ingenuity Pathway Analysis (IPA) software
(Qiagen Inc., https://www.qiagenbioinformatics.com/products/
FIGURE 1 | Ingenuity pathway analysis predicts the upstream and
downstream effects of activation or inhibition of the 13 genes from the distal
blood in a network. A red box indicates the gene is more extreme in the
dataset, while different shades of pink mean the gene is measured less in the
dataset. An orange box indicates the gene has more confidence in predicted
activation. Directional orange arrows indicate which gene leads to activation of
another gene. Yellow arrows indicate the findings are inconsistent with
downstream gene.
ingenuity-pathway-analysis) (34). IPA predicts the upstream
and downstream effects of activation or inhibition of the
13 genes from the distal blood in a pathway network. The
overall inflammatory chemokine/cytokine pattern from the distal
blood characterizes amicroenvironment for chemoattraction and
proliferation of immune cells, particularly in Th2 response and
neutrophils (Figure 1).
DISCUSSION
Our results revealed insights to the initial inflammatory response
to ischemic stroke in stroke patients. Arterial blood samples were
collected at one of the earliest timepoints (∼8 h and 35min from
LKN to thrombectomy completion time or infarct time) during
an ongoing stroke. Expression of 13 cytokines and chemokines
were induced over 2-fold in the distal blood relative to levels in
the proximal blood. Machine learning identified 10 genes, along
with age, T2DM, and BMI for predictors of infarct volume and 10
genes with T2DM for predictors of edema volume. In addition,
there was an overlap with seven genes and T2DM as predictors
for both stroke outcomes.
These seven genes are related to the Th2 response, which is a
T-cell response associated with allergy, cancer, and autoimmunity
(35, 36). One study has shown a systemic shift of the immune
system toward Th2 response at the late post-acute phase in
stroke patients after examining their peripheral venous blood
(37). IFNA2 is primarily produced by dendritic cells (38). This
cytokine is targeted as a treatment for the autoimmune disease,
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systemic lupus erythematosus (39). Exposure to INFA2 has
been linked to causing edema and been shown to induce the
production of cytokine IL-7 (40–42). IL-7 is required for T-
cell development and function (43, 44). The expression of IL-
4, a classic marker for Th2 cells, is increased by IL-7 and is
a direct cause of edema (45, 46). This cytokine’s activity is
targeted for diseases related to pathogenic T-cells (47). Th2 cells
express both CCR3 and CCR4 receptors that bind chemokines
to direct their migration to the site of injury or infection (48,
49). CCR3 is a chemokine receptor that has been shown to
mediate neuronal injury after ischemic insult (50). At least eight
different chemokines recognize this receptor and has shown
that its activation enhances choroidal neovascularization and
trafficking of eosinophils (51). Pharmaceutical companies have
targeted this receptor for the treatment of severe asthma (52).
CCR4 is another chemokine receptor and CCL17 and CCL22
are identified as high affinity ligands (53). This receptor is
highly expressed in thymus and peripheral blood leukocytes,
and is targeted for treatment in T-cell leukemia and peripheral
T-cell lymphoma (54). The cytokines, IL-5 and IL-9 are both
expressed and secreted by Th2 cells and are linked to edema
and infarct volume, respectively (55, 56). IL-5 is produced in
female mice express higher levels in the spleen relative to males
(57). Antagonists to IL-5 have been produced for the treatment
of severe asthma (58). Patients suffering from asthma have
higher levels of IL-9 producing T-cells in their peripheral blood
(59). While not targeted in a current treatment, systemically
applied neutralizing antibodies reduces infarct (56). Cytokine,
IL-27 has both pro-and anti-inflammatory effects and the main
source of activation is by antigen-presenting cells (60). IL-27
activates an inflammatory response by inducing CD4+ T-cells
into a Th1 response (61–64). However, IL-27 can also suppress
Th17 differentiation and inhibit inflammation enhancing a
Th2 response (65–68). In an experimental stroke model, mice
were administered IL-27 injections post-intracranial hemorrhage
(ICH) and demonstrated improved behavior tests, mobility, and
reduced edema around the hemorrhage sites (69).
Several limitations to this study should be noted. The sample
for this study was small and subjects were mostly Caucasian
due to hospital location. There was a potential for sampling bias
since this was a non-probability strategy and based on completed
mechanical thrombectomy procedures. A more diverse and
larger sample size is warranted in future studies. Standard
of care imaging for infarct and edema volumes were based
on CT and/or MRI imaging post-thrombectomy. Additional
imaging at discharge for comparison is warranted to understand
how thrombectomy relates to these stroke outcomes. Follow-
up assessment would be helpful to address subject’s long-term
recovery and functional status.
CONCLUSION
The machine learning (ML) algorithm has uncovered a
molecular/cellular signaling pathway that the literature supports
its relationship with the facilitation of infarct volume and edema.
Despite significant funding for stroke drug discovery, tPA and
mechanical thrombectomy are the only treatments. Identifying
the initial activators of the inflammatory response to stroke could
be therapeutic targets for treatment. The inhibition of these early
inflammatory events has the potential to block the inflammatory
cascade that occurs after a stroke that recruits the peripheral
immune system, which is involved in neurodegeneration that
lasts days afterward. The ML method has determined several
related genes are predictors of edema and infarct volume in
acute ischemic stroke patients. Thus, the use of ML to determine
molecular predictors from ischemic blood could initiate a new
approach for drug discovery in the field of stroke. Future studies
will utilize ML methods and examine expression of genes that
predict long-term functional outcomes.
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